7Baggers
Quarterly
Annual
    Unit: USD2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2013-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31 2009-12-31 2009-09-30 2009-06-30 2009-03-31 2008-12-31 2008-09-30 2008-06-30 2008-03-31 2007-09-30 2007-06-30 2007-03-31 
      
    		                                        
      operating activities
    		                                        
      net income
    		-49,500,000 -266,700,000 -261,300,000 -183,000,000 -88,000,000 -75,700,000 -56,400,000 -3,700,000 189,300,000 -32,700,000 4,600,000 69,700,000 185,400,000 39,500,000 92,700,000 -12,500,000 46,900,000 43,200,000 -9,600,000 -26,000,000 -8,805,000 26,900,000 -137,000 12,523,000 -23,173,000 23,888,000 11,944,000 9,434,000 1,918,000 3,661,000 -539,000 13,251,000 10,172,000 1,455,000 10,386,000 1,817,000 7,024,000 2,845,000 -4,960,000 -2,690,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                                        
      share-based compensation expense
    		     11,200,000 12,300,000 9,900,000  10,400,000 11,400,000 10,500,000    6,600,000  6,100,000 8,100,000 6,800,000                     
      depreciation and amortization
    		29,600,000 28,000,000 32,900,000 34,600,000 35,600,000 32,300,000 44,500,000 30,900,000 29,200,000 32,700,000 33,200,000 28,700,000 28,900,000 28,800,000 28,600,000 28,200,000 27,900,000 27,700,000 28,500,000 26,600,000 4,163,000 2,429,000 2,412,000 2,279,000 2,235,000 1,970,000 1,374,000 1,350,000 1,296,000 1,322,000 1,170,000 1,245,000 1,262,000 1,417,000 1,285,000 1,181,000 1,081,000 1,265,000 1,134,000 1,198,000 
      change in fair value of contingent obligations
    		600,000 -2,300,000 400,000 1,500,000                                     
      amortization of deferred financing costs
    		5,700,000 5,700,000 8,900,000 1,000,000 1,000,000 1,100,000 1,000,000 1,000,000 1,000,000 1,100,000 1,000,000 1,000,000 1,100,000 900,000 800,000 700,000 800,000 700,000 800,000 700,000                     
      deferred income taxes
    		-5,200,000 6,500,000 -1,800,000 -8,400,000 -42,000,000 20,400,000 700,000 1,900,000 46,300,000 3,800,000 -1,500,000 -1,700,000 2,000,000 -700,000 500,000 -4,200,000 4,600,000 -4,400,000 10,100,000 -11,400,000  8,251,000 8,808,000 250,000 2,879,000 6,413,000 1,079,000 2,618,000 819,000 368,000 5,896,000 407,000 933,000 1,821,000 822,000 -1,135,000 498,000 121,000 6,897,000 2,400,000 
      gain on sale of travel health business
    		0 700,000                                       
      goodwill impairment
    		0                                        
      impairment of long-lived assets
    		0 0                    300,000 483,000                  
      write off of contract asset and liability
    		                                        
      other
    		4,100,000 -600,000 9,200,000 300,000 -6,600,000 10,800,000 1,600,000 600,000 -3,100,000 3,100,000 -1,500,000 3,500,000 -5,800,000 -500,000   -900,000 -2,200,000 3,000,000 -100,000 6,000 332,000 17,000                  
      changes in operating assets and liabilities:
    		                                        
      accounts receivable
    		36,900,000 72,100,000 -132,400,000 1,800,000 38,500,000 -21,500,000 4,000,000 93,700,000 66,500,000 -80,000,000 -76,800,000 42,100,000 -25,600,000 62,500,000 -96,100,000 108,200,000 10,400,000 -63,200,000 -97,000,000 141,600,000 33,079,000 -25,205,000 -1,731,000 -35,287,000 27,350,000 -27,841,000 37,828,000 -12,360,000 21,467,000 -29,159,000 29,686,000 18,737,000 -49,281,000 -10,785,000 8,381,000 -933,000 -2,701,000 -22,616,000 -15,462,000 39,396,000 
      inventories
    		25,600,000 -1,200,000 5,800,000 -29,600,000 60,300,000 -36,700,000 -25,400,000 -50,100,000 14,000,000 21,700,000 20,200,000 -99,900,000 -35,600,000 -33,900,000 11,900,000 -25,600,000 7,700,000 1,700,000 -20,900,000 -5,200,000 -6,987,000 3,318,000 -717,000 4,901,000 -9,441,000 4,598,000 -204,000 -35,000 -3,560,000 2,295,000 -1,774,000 110,000 5,576,000 -2,212,000 1,363,000 -89,000 -1,893,000 3,263,000 -2,001,000 -2,163,000 
      prepaid expenses and other assets
    		30,000,000 -500,000 -13,300,000 -4,500,000 9,300,000 -9,800,000 -2,800,000 -16,600,000 30,100,000 -52,400,000 7,600,000 -10,000,000 32,600,000 -44,900,000 -1,600,000 -15,300,000 9,100,000 8,400,000 -28,300,000 -16,600,000 -246,000 390,000 -1,287,000 549,000 1,008,000 141,000 -953,000 -417,000 576,000 -1,443,000 -2,158,000 -8,000 2,379,000 -797,000 -943,000 -1,401,000 -405,000 -86,000 -731,000 -292,000 
      accounts payable
    		-7,100,000 6,800,000 -20,100,000 31,000,000 -5,000,000 -1,400,000 7,100,000 -14,700,000 -6,000,000 -4,500,000 -12,100,000 20,100,000 9,200,000 25,100,000 1,100,000 -15,600,000 14,000,000 -40,100,000 38,400,000 4,200,000 -4,196,000 2,391,000 885,000 -313,000 -453,000 -2,367,000 1,839,000 3,036,000 1,115,000 -5,706,000 5,521,000 -960,000 -189,000 708,000 -3,158,000 3,750,000 -1,757,000 2,722,000 -675,000 -2,735,000 
      accrued expenses and other liabilities
    		-25,500,000 -16,400,000 900,000 -14,700,000 31,300,000 -15,200,000 -26,300,000 -56,500,000 10,100,000 36,100,000 -15,400,000 -40,000,000         21,000 64,000 -185,000 20,000 6,000 133,000 -27,000 -475,000 146,000 -117,000 -52,000 223,000 -120,000 -1,399,000 1,365,000 -219,000 -270,000 171,000 749,000 -223,000 
      long-term incentive plan accrual
    		                                        
      accrued compensation
    		-9,600,000 12,600,000 11,900,000 -25,300,000 5,800,000 8,400,000 18,100,000 -32,200,000 15,100,000 10,300,000 8,000,000 -29,400,000 7,300,000 17,900,000 11,500,000 -14,900,000 6,600,000 11,100,000 7,800,000 -21,300,000 -10,982,000 5,937,000 912,000 136,000 -10,288,000 7,384,000 2,169,000 2,234,000 -5,580,000 763,000 4,201,000 1,676,000 -3,094,000 2,325,000 1,740,000 723,000 -2,910,000 6,000 2,887,000 -2,467,000 
      income taxes receivable and payable
    		-12,700,000 -17,700,000 1,300,000 12,900,000                                     
      contract liabilities
    		4,100,000 9,500,000 700,000 -8,400,000 5,400,000 1,500,000 4,700,000 -2,000,000 -12,300,000 -19,900,000 -9,000,000 9,400,000 20,200,000 -38,100,000 28,600,000 500,000                         
      net cash from operating activities
    		32,100,000 60,000,000 -114,400,000 -184,000,000 92,800,000 -74,000,000 -15,600,000 -37,300,000 329,000,000 16,700,000 -29,700,000 5,100,000 245,100,000 105,200,000 127,900,000 57,800,000 122,100,000 -3,100,000 -35,800,000 104,800,000 -4,626,000 38,564,000 4,836,000 -6,752,000 -22,055,000 24,178,000 54,172,000 3,792,000 17,401,000 -23,287,000 33,336,000 45,908,000 -25,446,000 -11,939,000 19,943,000 4,341,000 -5,028,000 -10,108,000 -28,373,000 14,786,000 
      capex
    		-14,900,000 -11,100,000 -12,600,000 -7,300,000 -24,200,000 -25,200,000 -38,100,000 -18,900,000 -47,300,000 -66,300,000 -800,000 -23,600,000 -36,000,000 -52,800,000 -25,600,000 -16,900,000 -36,100,000 -15,300,000 -14,100,000 -21,400,000 -7,679,000 -19,873,000 -17,358,000 -8,363,000 -8,432,000 -8,059,000 -5,411,000 -3,601,000 -5,030,000 -18,911,000 -5,282,000 -4,339,000 -4,755,000 -4,349,000 -3,921,000 -5,612,000 -6,294,000 -6,090,000 -11,833,000 -10,979,000 
      free cash flows
    		17,200,000 48,900,000 -127,000,000 -191,300,000 68,600,000 -99,200,000 -53,700,000 -56,200,000 281,700,000 -49,600,000 -30,500,000 -18,500,000 209,100,000 52,400,000 102,300,000 40,900,000 86,000,000 -18,400,000 -49,900,000 83,400,000 -12,305,000 18,691,000 -12,522,000 -15,115,000 -30,487,000 16,119,000 48,761,000 191,000 12,371,000 -42,198,000 28,054,000 41,569,000 -30,201,000 -16,288,000 16,022,000 -1,271,000 -11,322,000 -16,198,000 -40,206,000 3,807,000 
      investing activities
    		                                        
      purchases of property, plant and equipment
    		-11,400,000 -12,600,000 -12,500,000 -15,100,000 -23,600,000 -27,900,000 -32,100,000 -32,200,000 -46,700,000 -55,200,000           -7,679,000 -19,873,000 -17,358,000 -8,363,000 -8,432,000 -8,059,000 -5,411,000 -3,601,000 -5,030,000 -18,911,000 -5,282,000 -4,339,000 -4,755,000 -4,349,000 -3,921,000 -5,612,000 -6,931,000 -8,854,000 -10,853,000 -16,490,000 
      royalty settlement payment
    		                                        
      milestone payment from prior asset acquisition
    		0             0                           
      asset acquisitions
    		    0                                    
      proceeds from sale of travel health business
    		0 0                                       
      net cash from investing activities
    		-11,400,000 -18,900,000 257,700,000 -15,100,000                 -7,679,000 -18,340,000 -15,809,000 -7,073,000 -12,741,000 -9,414,000 -5,411,000 -3,601,000 -5,030,000 -18,911,000 -5,282,000 -4,339,000 -4,755,000 -4,349,000 -3,921,000 -12,112,000 -10,431,000 -13,854,000 -10,853,000 -16,490,000 
      financing activities
    		                                        
      purchases of treasury stock
    		    -200,000 0 -24,400,000 -57,500,000                                 
      principal payments on convertible senior notes
    		        0 0 0 -10,600,000                             
      proceeds from revolving credit facility
    		    360,000,000            0 0 100,000,000 30,000,000                     
      principal payments on revolving credit facility
    		-12,000,000 -39,000,000           0 -353,000,000 0 -20,000,000 -10,000,000 -15,000,000 0 -80,000,000                     
      principal payments on term loan facility
    		-3,900,000 -3,900,000 -148,400,000 -8,400,000 -8,500,000 -8,400,000 -8,400,000 -8,500,000 -8,400,000 -5,600,000 -5,700,000 -5,600,000 -5,700,000 -2,800,000 -2,800,000 -2,800,000 -2,900,000 -2,800,000 -2,800,000 -2,800,000                     
      proceeds from stock-based compensation activity
    		500,000 0                                       
      taxes paid for stock-based compensation activity
    		-100,000 -100,000 -200,000 -2,100,000                                     
      proceeds from at-the-market sale of stock, net of commissions and expenses
    		200,000 0                                       
      contingent consideration payments
    		        1,300,000 -1,400,000 -400,000 -700,000 -600,000 -1,100,000 -400,000 -700,000 -46,700,000 -2,700,000 -500,000 -500,000                     
      net cash from financing activities:
    		4,700,000 -43,000,000 -486,900,000 -10,500,000 353,100,000 229,300,000 -30,700,000 -70,500,000 -110,000,000 -5,000,000 -3,800,000 -22,200,000  87,100,000 4,700,000 -20,000,000  -19,700,000 100,100,000 -58,400,000                     
      effect of exchange rate changes on cash, cash equivalents and restricted cash
    		-1,500,000 1,100,000 -600,000 -200,000 1,100,000 -1,000,000 700,000 -300,000 0 -200,000 200,000 -300,000  -400,000 -200,000 100,000                         
      net change in cash, cash equivalents and restricted cash
    		23,900,000 -800,000   401,600,000 -117,300,000 -77,700,000 -140,300,000 172,300,000 -43,700,000 -100,300,000 -73,500,000                             
      cash, cash equivalents and restricted cash, beginning of period
    		0 0 0 642,600,000                                     
      cash, cash equivalents and restricted cash, end of period
    		23,900,000 -800,000 -341,600,000 430,200,000                                     
      supplemental cash flow disclosures:
    		                                        
      cash paid for interest
    		11,800,000 17,700,000 17,200,000 21,600,000                                     
      cash paid for income taxes
    		14,500,000 11,400,000 10,200,000 16,700,000                                     
      non-cash investing and financing activities:
    		                                        
      purchases of property, plant and equipment unpaid at period end
    		-3,500,000 1,500,000 -100,000 7,800,000 -600,000 2,700,000 -6,000,000 13,300,000 -600,000 -11,100,000 -800,000 32,500,000  -7,100,000 9,500,000 7,300,000                     637,000 2,764,000 -980,000 5,511,000 
      purchases of treasury stock unpaid at period end
    		                                        
      gain on extinguishment of debt
    		                                        
      stock-based compensation expense
    		 4,000,000 8,300,000 6,800,000         10,000,000 10,000,000       2,976,000 2,828,000 2,761,000 2,709,000 2,441,000 1,857,000 1,843,000 1,841,000 1,522,000 1,362,000 1,395,000 1,390,000 860,000 777,000 747,000 756,000 230,000 735,000 631,000 529,000 
      long-term incentive plan expense
    		 1,300,000                                       
      supplemental disclosure of cash flow information:
    		                                        
      supplemental information on non-cash investing and financing activities:
    		                                        
      net change in cash, cash equivalents and restricted cash excluding cash classified within assets held for sale
    		   -209,800,000                                     
      add: net change in cash, classified within current assets held for sale
    		   -2,600,000                                     
      reconciliation of cash and cash equivalents and restricted cash at march 31, 2023 and december 31, 2022:
    		                                        
      cash and cash equivalents
    		   430,200,000 401,700,000 -117,200,000 -77,700,000 435,800,000 172,300,000 -43,700,000 -100,300,000 547,800,000 206,300,000 146,200,000 87,300,000 181,500,000                         
      cash and cash equivalents included in assets held for sale
    		   2,600,000                                     
      total
    		   432,800,000 401,600,000 -117,300,000 -77,700,000 436,000,000 172,300,000 -43,700,000 -100,300,000 548,000,000 206,300,000 146,200,000 87,300,000 181,700,000                         
      impairments
    		                                        
      proceeds from senior unsecured notes
    		            0                            
      debt issuance costs
    		            0                            
      reconciliation of cash and cash equivalents and restricted cash:
    		                                        
      restricted cash
    		     -100,000 0 200,000 0 0 0 200,000 0 0 0 200,000                         
      cash flows used in operating activities:
    		                                        
      adjustment for prior period lease receivables
    		                                        
      change in fair value of contingent consideration
    		     600,000 1,300,000 500,000  900,000 600,000 1,100,000 400,000 30,200,000 500,000 600,000 12,400,000 6,900,000 3,800,000 1,700,000                     
      cash flows used in investing activities:
    		                                        
      net cash from investing activities:
    		     -271,600,000 -32,100,000 -32,200,000  -55,200,000 -67,000,000 -56,100,000 -36,000,000 -45,700,000 -45,100,000 -24,200,000 -36,100,000 -15,300,000 -24,100,000 -21,400,000                     
      cash flows from financing activities:
    		                                        
      proceeds from share-based compensation activity
    		     0 2,500,000 500,000  2,500,000 3,100,000 6,900,000                             
      taxes paid for share-based compensation activity
    		     -300,000 -400,000 -5,000,000  -500,000 -800,000 -12,200,000 -1,000,000 -1,100,000                           
      cash, cash equivalents and restricted cash at beginning of period
    		     0 0 576,300,000 0 0 0 621,500,000  0 0 168,000,000  0 0 112,400,000                     
      cash, cash equivalents and restricted cash at end of period
    		     -117,300,000 -77,700,000 436,000,000 172,300,000 -43,700,000 -100,300,000 548,000,000  146,200,000 87,300,000 181,700,000  -38,200,000 40,200,000 137,400,000                     
      cash paid during the period for interest
    		     11,900,000 3,100,000 11,700,000  11,800,000 3,100,000 12,400,000  2,400,000 4,200,000 7,400,000                      699,000 874,000 644,000 
      cash paid during the period for income taxes
    		     3,900,000 15,200,000 4,800,000  7,300,000 48,800,000 1,500,000  75,100,000 8,600,000 3,600,000                      369,000 1,460,000 12,500,000 
      reconciliation of cash and cash equivalents and restricted cash at september 30, 2022 and december 31, 2021:
    		                                        
      cash flows used in financing activities:
    		                                        
      reconciliation of cash and cash equivalents and restricted cash at june 30, 2022 and december 31, 2021:
    		                                        
      cash flows from operating activities:
    		                                        
      reconciliation of cash and cash equivalents and restricted cash at march 31, 2022 and december 31, 2021:
    		                                        
      cash flows from investing activities:
    		                                        
      cash paid during the year for interest
    		                                        
      cash paid during the year for income taxes
    		                                        
      impairment of ipr&d
    		                                        
      reconciliation of cash and cash equivalent and restricted cash at september 30, 2021 and december 31, 2020:
    		                                        
      adjustments to reconcile to net income to net cash from operating activities:
    		                                        
      reconciliation of cash and cash equivalent and restricted cash at june 30, 2021 and december 31, 2020:
    		                                        
      purchases of property, plant and equipment and other
    		           -56,100,000 -36,000,000 -45,700,000 -35,100,000 -24,200,000 -36,100,000 -15,300,000 -14,100,000 -21,400,000                     
      reconciliation of cash and cash equivalent and restricted cash at march 31, 2021 and december 31, 2020:
    		                                        
      adjustments to reconcile to net cash from operating activities:
    		                                        
      impairment of ipr&d intangible asset
    		            0                            
      milestone payment from asset acquisition
    		                0                        
      business acquisitions, net of cash acquired
    		                                        
      proceeds from sale of assets
    		                                        
      proceeds from term loan facility
    		                                        
      receipts and payments of restricted cash
    		                                        
      purchase of treasury stock
    		                                        
      net cash from financing activities
    		                    995,000 -2,454,000 14,347,000 -1,037,000 3,395,000 2,963,000 807,000 -14,002,000 874,000 26,692,000 -11,870,000 -166,000 188,000 2,892,000 4,484,000 -700,000 2,292,000 14,411,000 5,872,000 -6,899,000 
      effect of exchange rate changes on cash and cash equivalents
    		                    -118,000 785,000 -122,000 31,000 -693,000 63,000 -532,000 -380,000 215,000 -347,000 85,000 -275,000 -80,000 181,000 175,000 -269,000 184,000 -163,000 -311,000 -170,000 
      net change in cash and cash equivalents and restricted cash
    		                                        
      cash and cash equivalents and restricted cash at beginning of year
    		                                        
      cash and cash equivalents and restricted cash at end of year
    		                                        
      issuance of common stock to acquire adapt pharma
    		                                        
      purchases of property, plant and equipment unpaid at year end
    		                                        
      accrued expenses
    		             -20,600,000 23,900,000 1,100,000  -1,700,000 5,200,000 1,700,000                     
      proceeds from exercise of stock options
    		             3,500,000                           
      net increase in cash, cash equivalents and restricted cash
    		             146,200,000 87,300,000 13,700,000  -38,200,000 40,200,000 25,000,000                     
      reconciliation of cash and cash equivalent and restricted cash at september 30, 2020 and december 31, 2019:
    		                                        
      reconciliation of cash and cash equivalent and restricted cash at june 30, 2020 and december 31, 2019:
    		                                        
      proceeds from issuance of common stock upon exercise of stock options
    		               9,100,000                         
      taxes paid on behalf of employees for equity activity
    		               -5,600,000 -800,000 -300,000 -300,000 -6,000,000                     
      reconciliation of cash and cash equivalent and restricted cash at march 31, 2020 and december 31, 2019:
    		                                        
      share-based compensation
    		                                        
      income taxes
    		                    -7,918,000 17,182,000 -7,352,000 6,830,000 -15,238,000 4,478,000 -4,418,000 -3,755,000 -2,459,000 -1,064,000 -10,680,000 3,620,000 4,599,000 -1,947,000 -1,210,000 228,000 -3,785,000 1,801,000 -9,935,000 -17,686,000 
      deferred revenue
    		                  14,300,000 2,100,000 197,000 -5,778,000 -1,149,000 -1,450,000 -2,486,000 -821,000 12,000 0 -14,000 0 -223,000   -2,441,000 -408,000 -144,000 -150,000 -335,000 -199,000 -481,000 
      payment of notes payable to aptevo
    		                                        
      net increase in cash and cash equivalents and restricted cash
    		                                        
      cash flows from provided by financing activities:
    		                                        
      issuances of stock under share-based benefit plans
    		                 1,100,000 3,700,000 900,000                     
      stock-based compensation
    		                                        
      impairment and abandonment of long-lived assets
    		                                        
      excess tax benefits from stock-based compensation
    		                    -1,608,000 -698,000 284,000 -1,747,000 -39,000 -623,000 -368,000 -333,000 -376,000 -297,000 -1,042,000 -317,000 -196,000     0   
      changes in operating assets and liabilities, net of business acquisitions:
    		                                        
      proceeds from long-term debt obligations
    		                                        
      principal payments on long-term indebtedness
    		                    -1,117,000                    
      distribution to aptevo
    		                                        
      net decrease in cash and cash equivalents
    		                                -30,093,000  20,681,000 -8,740,000 -12,983,000 -9,714,000 -33,665,000 -8,773,000 
      cash and cash equivalents at beginning of year
    		                                        
      cash and cash equivalents at end of year
    		                                        
      impairment of intangible assets
    		                                        
      bad debt expense
    		                                        
      benefit from chargebacks
    		                                        
      acquisitions
    		                                        
      issuance of common stock upon exercise of stock options
    		                                        
      payments of notes payable
    		                                        
      net increase in cash and cash equivalents
    		                    -11,428,000 18,555,000 3,252,000 -14,831,000 -32,094,000 17,790,000 49,036,000 -14,191,000 13,460,000 -15,853,000 16,269,000          
      write off of debt issuance costs
    		                                        
      acquisitions, net of acquired cash
    		                                        
      proceeds from convertible debenture, net of bank fees
    		                                        
      contingent obligation payments
    		                                        
      non-cash development expenses from joint venture
    		                    190,000     3,754,000 2,056,000 168,000 17,000 1,189,000 1,938,000 2,455,000 1,633,000        
      impairment of in-process research and development
    		                                        
      proceeds from maturity of investments
    		                     500,000 1,500,000                  
      purchase of investments
    		                     1,033,000 49,000 -960,000 -4,309,000                
      acquisition of healthcare protective products division
    		                                        
      proceeds from borrowings on long-term indebtedness
    		                                        
      issuance of common stock subject to exercise of stock options
    		                    504,000 1,190,000 141,000 4,497,000 4,198,000 3,179,000 1,272,000 1,531,000 1,253,000 271,000 3,059,000 483,000 651,000 2,771,000 406,000   55,000 1,529,000 890,000 
      principal payments on long-term indebtedness and line of credit
    		                     -563,000 -6,808,000 -7,281,000 -842,000 -837,000 -833,000 -15,866,000 -15,755,000 -1,052,000 -15,971,000 -15,966,000 -15,659,000        
      restricted cash deposit
    		                                        
      current and deferred income taxes
    		                    -4,516,000                    
      change in fair value of contingent value rights
    		                     -1,104,000 -83,000                  
      contingent value right payment
    		                                        
      cash and cash equivalents at beginning of period
    		                    141,666,000  0 0 169,019,000  0 0 102,924,000  0 0 91,473,000  0 0 105,730,000 0 0 76,418,000 
      cash and cash equivalents at end of period
    		                    130,238,000  3,252,000 -14,831,000 136,925,000  49,036,000 -14,191,000 116,384,000  16,269,000 41,128,000 61,380,000  20,681,000 -8,740,000 92,747,000 -9,714,000 -33,665,000 67,645,000 
      benefit from impairment of accrued interest on note receivable
    		                                        
      acquisition of trubion pharmaceuticals, inc., net of cash acquired
    		                                        
      repayment of note receivable
    		                                        
      proceeds from borrowings on long-term indebtedness and line of credit
    		                     6,224,000       15,000,000    15,000,000        
      issuance of common stock to acquire trubion pharmaceuticals, inc.
    		                                        
      non-cash development expenses from variable interest entities
    		                      915,000                  
      proceeds from borrowing on line of credit
    		                                        
      non-cash development expenses from joint ventures
    		                        2,550,000                
      gain on disposal of property and equipment
    		                        13,000    -34,000     47,000 1,000      
      benefit from impairment of long-lived assets
    		                         189,000 0 481,000 548,000 3,510,000 0          
      benefit from fair value of contingent value rights
    		                        581,000                
      proceed from maturities of investments
    		                                        
      repayment/(issuance) of note receivable
    		                                        
      restricted cash release
    		                                 -8,000       
      (gain) loss on disposal of property, plant and equipment
    		                                        
      proceeds from borrowings on line of credit
    		                          0              
      (gain) loss on disposal of property and equipment
    		                                        
      issuance of note receivable
    		                                        
      gain on disposal of property, plant and equipment
    		                              -3,000          
      proceeds from line of credit
    		                                        
      loss on disposal of property and equipment
    		                                25,000    10,000    
      adjustments to reconcile net income to net cash from operating activities
    		                                        
      purchased in-process research and development
    		                                        
      acquisitions, net of cash received
    		                                        
      proceeds from borrowings on long term indebtedness and line of credit
    		                                 15,000,000 15,000,000      
      issuance of common stock in initial public offering
    		                                        
      redemption of class b common stock
    		                                        
      principal payments on long term indebtedness, notes payable to employees, and line of credit
    		                                        
      minority interest in subsidiary
    		                                        
      issuance of a note receivable
    		                                        
      principal payments on long term indebtedness and line of credit
    		                                        
      principal payments on long term indebtedness and line of credits
    		                                        
      issuance of notes receivable
    		                                    -3,500,000    
      proceeds from borrowings on long term indebtedness and lines of credit
    		                                    15,000,000    
      principal payments on long term indebtedness, notes payable to employees, and lines of credits
    		                                    -12,708,000   -9,386,000 
      restricted cash deposits
    		                                        
      principal payments on long term indebtedness, notes payable to employees, and lines of credit
    		                                     -977,000   
      proceeds from excess tax benefits
    		                                       1,597,000 
      non-cash gain on settlement
    		                                        
      other obligations
    		                                        
      excess tax benefit from stock based compensation
    		                                        
      proceeds from investment maturities
    		                                        
      proceeds from notes payable to employees
    		                                        
      repayments on product supply and royalty obligations
    		                                        
      payment of dividend
    		                                        
      issuance of common stock to acquire microscience limited
    		                                        
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.